Cloning and Expression of the para-Hydroxybenzoate Hydroxylase Gene from Pseudomonas aeruginosa and ...

謝佩芬、簡宏堅

E-mail: 9701206@mail.dyu.edu.tw

ABSTRACT

L-DOPA is a medicine to prevent Parkinson's disease getting worse, therefore para-hydroxybenzoate hydroxylase (HBHD)from Pseudomonas aeruginosa PAO1 was chosen to substitute for tyrosine hydroxylase to transform L-tyrosine become L-DOPA to achieve the treatment. So hbhd gene was used as template to design primer pair. Chromosome DNA of P. aeruginosa PAO1 was used as template to amplify hbhd gene by PCR. Cloning of hbhd gene into Escherichia coli and expression of enzymatic activities were performed. The length of hbhd performed open reading frame (ORF) was 1,185 bp. The translation HBHD product was 45 kDa of molecular weight. The P. aeruginosa hbhd gene was cloned into pQE30 expression vecter and transformated to E. coli Nova Blue. Finally, Ni-NTA column was used to purify the enzyme. With the para-hydroxybenzoate as subtrate, enzyme activity was maximal at 80 , the optimum pH 9.0 assayed by high performance liquid chromatography, Fe2+ ion promoted enzyme activity. When the concentration of para-hydroxybenzoate reached to 100 mM, enzyme activity was measured without any substrate inhibition. With the L-tyrosine as substrate, enzyme activity was maximal at 30 , the optimum pH 3.5 characterized by HPLC. Without metal ion, the HBHD is still active. When the concentrations of L-tyrosine and L-DOPA reached to 80 mM and 3.8 mM, the HBHD activity was reduced to 50 % with the substrate and product inhibition, respectively.

Keywords: L-DOPA; gene cloning; igh performance liquid chromatography

Table of Contents

授權書	iii 中文摘要	iv 英文摘要	v 誌	
謝	vi 目錄	vii 圖目錄	ix 表目	
錄	xi 1. 前言	1 2. 材料與方法	4 2.1 實驗材	
料	4 2.2 實驗方法	4 2.2.1 Pseudomonas ae	ruginosa PAO1染色體萃取 4 2.2.2	引子
(primer) 設計	5 2.2.3 聚合? 一嚍磥狨	(Polymerase chain reaction, PCF	국) 6 2.2.4 限制	酵素剪
切 (restriction enzyme d	ligestion) 7 2.2.5 DNA	.黏合作用 (Ligation)8	2.2.6 質體的轉形作用 (transformation	on)
8 2.2.6.1 大腸桿菌 (E.	coli) 勝任細胞 (comptent Ce	ell) 的製備 8 2.2.6	.2 E. coli的轉形作用 (transfprmation) 9
2.2.7 E. coli質體 (plasm	nid) DNA的抽取 9 2.2.	8 DNA定序及序列比對	10 2.2.9 para-hydroxybenzoate	
hydroxylase (HBHD)	基因少量表現	10 2.2.10 HBHD基因大量	表現與蛋白回收 11 2.2.11 H	IBHD酵
素活性分析	12 2.2.11.1 高效液相層	析法(High performance liquid c	hromatography, HPLC)122	.2.11.2
HBHD最適反應pH	13 2.2.11.3 HBł	HD最適反應溫度14	2.2.11.4 金屬離子對HBHD活性影	
響14 2.2.11.5	HBHD之受質抑制	15 2.2.11.6 HBHD之產物	抑制 15 2.2.11.7 HBH	D之受質
專一性16	3. 結果	17 4. 討論	20 參考文獻	45
附錄	47			

REFERENCES

1. Boonyapiwat B, Forbes B, Steventon GB. (2004) Phenylalanine hydroxylase: possible involvement in the S-oxidation of S-carboxymethyl-I-cysteine. Anal Biochem. 1;335(1):91-7. 2. Costa RM, Lin SC, Sotnikova TD, Cyr M, Gainetdinov RR, Caron MG, Nicolelis MA. (2006) Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron 52(2):359-69.

3. Daubner SC, Fitzpatrick PF. (1998) Mutation to phenylalanine of tyrosine 371 in tyrosine hydroxylase increases the affinity for phenylalanine. Biochemistry. 37(46):16440-4. 4. Entsch B, Palfey BA, Ballou DP, Massey V. (1991) Catalytic function of tyrosine residues in para-hydroxybenzoate hydroxylase as determined by the study of site-directed mutants. J Biol Chem. 266(26):17341-9. 5. Eppink MH, Schreuder HA, van Berkel WJ. (1998) Lys42 and Ser42 variants of p-hydroxybenzoate hydroxylase from Pseudomonas fluorescens reveal that Arg42 is essential for NADPH binding. Eur J Biochem. 253(1):194-201. 6. Fujii T, Kaneda T. (1985) Purification and properties of NADH/NADPH-dependent p-hydroxybenzoate hydroxylase from Corynebacterium cyclohexanicum. Eur J Biochem. 147(1):97-104. 7. Ginns EI, Rehavi M, Martin BM, Weller M, O'Malley KL, LaMarca ME, McAllister CG, Paul SM.(1988) Expression of human tyrosine hydroxylase cDNA in invertebrate cells

using a baculovirus vector. J Biol Chem. 263(15):7406-10. 8. King EO, Ward MK, Raney DE (1970) Two simple media for the demonstration of pyocyanin and fluorescin. J Lab Clin Med. 44 (2):301-7. 9. Mulholland AJ andRidder L. (2003) Caught in the act: modelling how a biological catalyst works. CSAR Focus 10,12-13. 10. Nishimura M, Kumamoto Y, Shibuya A, Hirose T, Tsukamoto T, Ohya S. (1990) An in vitro study on the treatment of complicated cystitis using an automatic simulator. Kansenshogaku Zasshi. 64(8):1004-12. 11. Randhir, T.O. (2003)

Watershed-scale effects of urbanization on sediment export: Assessment and policy. Water Resour Res. 39(6):1-13. 12. Saiki I, Murata J, Iida J, Sakurai T, Nishi N, Matsuno K, Azuma I...(1989) Antimetastatic effects of synthetic polypeptides containing repeated structures of the cell adhesive Arg-Gly-Asp (RGD) and Tyr-Ile-Gly-Ser-Arg (YIGSR) sequences. Br J Cancer. 60(5):722-8. 13. Seibold B, Matthes M, Eppink MH, Lingens F, Van Berkel WJ, Muller R. (1996) 4-Hydroxybenzoate hydroxylase from Pseudomonas sp. CBS3. Purification, characterization, gene cloning, sequence analysis and assignment of structural features determining the coenzyme specificity. Eur J Biochem. 239(2):469-78. 14. Van Berkel W, Westphal A, Eschrich K, Eppink M, de Kok A. (1992) Substitution of Arg214 at the substrate-binding site of p-hydroxybenzoate hydroxylase from Pseudomonas fluorescens. Eur J Biochem. 210(2):411-9. 15. Vervoort J, Rietjens IM, van Berkel WJ, Veeger C. (1992) Frontier orbital study on the 4-hydroxybenzoate-3-hydroxylase-dependent activity with benzoate derivatives. Eur J Biochem. 206(2):479-84. 16. Wijnands RA, Muller F. (1982) A study of p-hydroxybenzoate hydroxylase from Pseudomonas fluorescens: chemical modification of histidine residues. Biochemistry. 21(26):6639-46.